Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM)

被引：7

作者：

Villalba, Ana ^{[1
]}

Pilar Gonzalez-Rodriguez, Ana ^{[2
]}

Arzuaga-Mendez, Javier ^{[3
]}

Puig, Noemi ^{[4
]}

Arnao, Mario ^{[1
]}

Maria Arguinano, Jose ^{[5
]}

Jimenez, Maria ^{[6
]}

Canet, Marta ^{[7
]}

Teruel, Ana, I ^{[8
]}

Sola, Maria ^{[9
]}

Diaz, Francisco J. ^{[10
]}

Encinas, Cristina ^{[11
]}

Garcia, Antonio ^{[12
]}

Rosinol, Laura ^{[13
]}

Suarez, Alexia ^{[14
]}

Sonia Gonzalez, Marta ^{[15
]}

Izquierdo, Isabel ^{[16
]}

Teodoro Hernandez, Miguel ^{[17
]}

Stefania Infante, Maria ^{[18
]}

Jose Sanchez, Maria ^{[19
]}

Sampol, Antonia ^{[20
]}

de la Rubia, Javier ^{[1
,21
,22
]}

机构：

[1] Hosp Univ & Politecn La Fe, Hematol Dept, Valencia, Spain

[2] Hosp Univ Cent Asturias HUCA Oviedo, Hematol Dept, Oviedo, Spain

[3] Hosp Univ Cruces, Biocruces Bizkaia Hlth Res Inst, Hematol Dept, Grp Canc Hematol, Baracaldo, Spain

[4] Hosp Univ Salamanca HUSAL, Hematol Dept, CIBERONC, IBMCC USAL CSIC,IBSAL, Salamanca, Spain

[5] Complejo Hosp Navarra, Hematol Dept, Pamplona, Spain

[6] Hosp Univ Dr Peset, Hematol Dept, Valencia, Spain

[7] Hosp Univ Mutua Terrasa, Hematol Dept, Terrassa, Spain

[8] Hosp Clin Univ, Hematol Dept, Valencia, Spain

[9] Hosp Univ Morales Meseguer, Hematol Dept, Murcia, Spain

[10] Hosp Univ Burgos, Hematol Dept, Burgos, Spain

[11] Hosp Gen Univ Gregorio Maranon HGUGM, Hematol Dept, IiSGM, Madrid, Spain

[12] Hosp Arnau Vilanova, Hematol Dept, Lleida, Spain

[13] Hosp Clin Barcelona, Hematol Dept, Barcelona, Spain

[14] Hosp Gran Canaria Doctor Negrin, Hematol Dept, Las Palmas Gran Canaria, Municipality Of, Spain

[15] H Clin Univ Santiago Compostela, Hematol Dept, La Coruna, Spain

[16] Hosp Univ Miguel Servet, Hematol Dept, Zaragoza, Spain

[17] Hosp Univ Canarias, Hematol Dept, Santa Cruz De Tenerife, Spain

[18] Hosp Univ Infanta Leonor, Hematol Dept, Madrid, Spain

[19] Hosp Univ Lucus Augusti, Hematol Dept, Lugo, Spain

[20] Hosp Univ Son Espases, Hematol Dept, Palma De Mallorca, Spain

[21] Univ Catolica San Vicente Martir, Hematol Dept, Valencia, Spain

[22] CIBERONC CB16-12-00284, Valencia, Spain

来源：

LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 14期

关键词：

Multiple myeloma; autologous stem cell transplantation; high-risk cytogenetics; tandem transplantation; MINIMAL RESIDUAL DISEASE; DEXAMETHASONE; BORTEZOMIB; LENALIDOMIDE; SURVIVAL; CRITERIA; THERAPY; MAINTENANCE; MELPHALAN; CONSENSUS;

D O I：

10.1080/10428194.2022.2123229

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tandem ASCT has been suggested as a valid approach to improve the prognosis of patients with MM and HR cytogenetic. In this observational, retrospective study, 213 patients with newly diagnosed MM and HR cytogenetic in 35 hospitals from the Spanish Myeloma Group underwent single or tandem ASCT between January 2015 and December 2019 after induction with VTD/VRD. HR cytogenetic was defined as having >= 1 of the following: del17p, t(4;14), t(14;16) or gain 1q21. More patients in the tandem group had R-ISS 3 and >1 cytogenetic abnormality at diagnosis. With a median follow-up of 31 months (range, 10-82), PFS after single ASCT was 41 months versus 48 months with tandem ASCT (p = 0.33). PFS in patients with del17p undergoing single ASCT was 41 months, while 52% of patients undergoing tandem ASCT were alive and disease free at 48 months. In conclusion, tandem ASCT partly overcomes the bad prognosis of HR cytogenetic.

引用

页码：3438 / 3447

页数：10

共 50 条

[41] Comparative analysis of single versus tandem autologous stem cell transplantation in patients with multiple myeloma in Korea: the KMM2102 study
Jung, Jongheon
Jung, Sung-Hoon
Lee, Je-Jung
Do, Young Rok
Kang, Ka-Won
Lee, Jung Lim
Yoon, Sung-Soo
Min, Chang-Ki
Kang, Hye Jin
Lee, Ji Hyun
Park, Ju-Hyun
Kim, Kihyun
Eom, Hyeon-Seok
SCIENTIFIC REPORTS, 2024, 14 (01):
[42] High-dose therapy/stem cell support (HDT), including tandem transplant, for primary refractory multiple myeloma (MM): Results from the Spanish myeloma group (PETHEMA/GEM) in 49 patients.
Rosinol, L
Garcia-Sanz, R
Lahuerta, JJ
Hernandez-Garcia, M
Sureda, A
de la Rubia, J
Ribera, JM
Hernandez-Ruiz, B
Carreras, D
Navarro, I
Garcia-Ruiz, JC
Gardella, S
Garcia-Larana, J
Diaz-Mediavilla, J
San Miguel, JF
Blade, J
BLOOD, 2005, 106 (11) : 456B - 456B
[43] Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results
Morgan, Gareth J.
Davies, Faith E.
Gregory, Walter M.
Bell, Sue E.
Szubert, Alexander J.
Coy, Nuria Navarro
Cook, Gordon
Feyler, Sylvia
Johnson, Peter R. E.
Rudin, Claudius
Drayson, Mark T.
Owen, Roger G.
Ross, Fiona M.
Russell, Nigel H.
Jackson, Graham H.
Child, J. Anthony
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (03): : 442 - 450
[44] Long-term outcomes of single/tandem autologous haematopoietic progenitor cell transplantation in high-risk de novo multiple myeloma patients: a retrospective analysis
Martino, M.
Fedele, R.
Console, G.
Messina, G.
Irrera, G.
Callea, V.
Piro, E.
Musolino, C.
Brugiatelli, M.
Molica, S.
Abbadessa, A.
Morabito, F.
Iacopino, P.
BONE MARROW TRANSPLANTATION, 2010, 45 : S150 - S150
[45] Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial
Cook, Gordon
Ashcroft, A. John
Senior, Ethan
Olivier, Catherine
Hockaday, Anna
Richards, Jeanine
Cavenagh, Jamie D.
Snowden, John A.
Drayson, Mark T.
de Tute, Ruth
Roberts, Lesley
Owen, Roger G.
Yong, Kwee
Garg, Mamta
Boyd, Kevin
Sati, Hamdi
Gillson, Sharon
Cook, Mark
Cairns, David A.
Parrish, Christopher
LANCET HAEMATOLOGY, 2024, 11 (11): : E816 - E829
[46] Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study
Habib, Joyce
Dunavin, Neil
Phillips, Gary
Elder, Patrick
Tranovich, Meaghan
Benson, Don M., Jr.
Hofmeister, Craig C.
Byrd, John C.
Devine, Steven M.
Efebera, Yvonne
BLOOD, 2010, 116 (21) : 575 - 576
[47] Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation
Kazmi, Syed M.
Nusrat, Maliha
Gunaydin, Hilal
Cornelison, Amanda M.
Shah, Nina
Kebriaei, Partow
Nieto, Yago
Parmar, Simrit
Popat, Uday R.
Oran, Betul
Shah, Jatin J.
Orlowski, Robert Z.
Champlin, Richard E.
Qazilbash, Muzaffar H.
Bashir, Qaiser
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (11): : 687 - 693
[48] A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF ELOTUZUMAB MONOTHERAPY IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA
Richardson, P.
Wong, E.
Stockerl-Goldstein, K.
Rosenbaum, C.
Dhodapkar, M.
Jou, Y. M.
Lynch, M.
Robbins, M.
Bleickardt, E.
Jagannath, S.
HAEMATOLOGICA, 2016, 101 : 328 - 329
[49] UP-FRONT HIGH DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: SINGLE CENTER RETROSPECTIVE ANALYSIS OF 124 CASES
Tsukada, Nobuhiro
Nomura, Moe
Kasuya, Yuki
Oda, Yuki
Takei, Tomomi
Sato, Kota
Ogura, Mizuki
Kikuchi, Taku
Abe, Yu
Suzuki, Kenshi
Ishida, Tadao
BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 492 - 492
[50] High-Risk Cytogenetics in Newly Diagnosed Multiple Myeloma: Prognostic Relevance of Co-Segregations and Analysis of the Role of Double Versus Single Autotransplantation
Testoni, Nicoletta
Marzocchi, Giulia
Pantani, Lucia
Ameli, Gaia
Dozza, Luca
Gay, Francesca
Petrucci, Maria Teresa
Di Raimondo, Francesco
Patriarca, Francesca
Galli, Monica
Montefusco, Vittorio
Gamberi, Barbara
Crippa, Claudia
Vincelli, Donatella Iolanda
Offidani, Massimo
Terragna, Carolina
Mancuso, Katia
Rocchi, Serena
Sonneveld, Pieter
Boccadoro, Mario
Cavo, Michele
BLOOD, 2017, 130

← 1 2 3 4 5 →